Avalyn Pharma Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

General form for quarterly reports under Section 13 or 15(d)

Results of Operations and Financial Condition

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G) (amendment)

Entry into a Material Definitive Agreement

Regulation FD Disclosure

General form for quarterly reports under Section 13 or 15(d)

Results of Operations and Financial Condition

Beneficial ownership report for a holder of more than 5% (Schedule 13D)

Beneficial ownership report for a holder of more than 5% (Schedule 13D)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Prospectus Supplement with Pricing Information

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Amended Initial Registration Statement

Certification of approval for listing and registration on a national securities exchange

Registration of Securities on Exchange

Amended Initial Registration Statement

Registration (IPO) statement under Securities Act of 1933

Draft registration statement (confidential submission) (amendment)

Draft registration statement (confidential submission)

06b

06b

<ITEMS>06b

06b

06b

06b

06

Meyer Robert J.

Meyer Robert J.

Novo Holdings A/S

FMR LLC

Golden Adam H.

Carlson Douglas R

Baranowski Lyn

Lavelle Erin

Lazarus Howard

Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

Haviland Kate

Rhodes Melissa

Turner Heather D